H.C. Wainwright analyst Edward White initiated coverage with a Buy rating on Curis (CRIS) today and set a price target of $5.00. The company’s shares closed last Monday at $1.35.
According to TipRanks.com, White is a 5-star analyst with an average return of 34.8% and a 54.2% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Allena Pharmaceuticals.
Currently, the analyst consensus on Curis is a Moderate Buy with an average price target of $5.00, which is a 281.7% upside from current levels. In a report issued on November 11, JonesTrading also reiterated a Buy rating on the stock with a $5.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.59 and a one-year low of $0.62. Currently, Curis has an average volume of 533.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
